Aurinia Pharmaceuticals Inc. Share Price Toronto S.E.
Equities
AUP
CA05156V1022
Biotechnology & Medical Research
Sales 2024 * | 227M 310M 18.09B | Sales 2025 * | 282M 386M 22.48B | Capitalization | 716M 978M 57.04B |
---|---|---|---|---|---|
Net income 2024 * | 9M 12.29M 717M | Net income 2025 * | 71M 96.99M 5.65B | EV / Sales 2024 * | 1.41 x |
Net cash position 2024 * | 395M 540M 31.48B | Net cash position 2025 * | 448M 612M 35.66B | EV / Sales 2025 * | 0.95 x |
P/E ratio 2024 * |
86.6
x | P/E ratio 2025 * |
10.6
x | Employees | 300 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.47% |
Latest transcript on Aurinia Pharmaceuticals Inc.
Managers | Title | Age | Since |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 15/06/93 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 28/04/19 |
Robert Foster
FOU | Founder | 65 | 15/06/93 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 15/06/93 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 25/06/19 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 28/04/19 |
1st Jan change | Capi. | |
---|---|---|
+5.66% | 111B | |
+11.23% | 105B | |
-12.15% | 22.34B | |
-2.68% | 21.93B | |
-5.61% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |